MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.95
+0.22 (2.05%)
At close: Apr 24, 2026, 4:00 PM EDT
10.94
-0.01 (-0.09%)
After-hours: Apr 24, 2026, 7:03 PM EDT
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
54.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 43.77M |
| Cue Biopharma | 27.47M |
| Metagenomi Therapeutics | 25.21M |
| Radiopharm Theranostics | 10.86M |
| Plus Therapeutics | 5.21M |
| Entera Bio | 42.00K |
INKT News
- 21 days ago - MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - GlobeNewsWire
- 23 days ago - MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference - GlobeNewsWire
- 24 days ago - MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum - GlobeNewsWire
- 5 weeks ago - MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs - GlobeNewsWire
- 6 weeks ago - Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? - Benzinga
- 6 weeks ago - MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally - Benzinga
- 6 weeks ago - MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia - GlobeNewsWire